CF 1743

Drug Profile

CF 1743

Alternative Names: CF-1743

Latest Information Update: 14 Jul 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rega Institute for Medical Research; University of Wales
  • Developer FermaVir Pharmaceuticals
  • Class Antivirals; Nucleosides; Pyrimidines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Herpes zoster

Most Recent Events

  • 14 Jul 2009 Discontinued - Preclinical for Herpes zoster in USA (Topical)
  • 20 Sep 2007 FermaVir Pharmaceuticals has been acquired by Inhibitex
  • 20 Sep 2007 Data presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2007) added to the Viral Infections antimicrobial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top